At the recent IMPAKT Breast Cancer Conference, 2 – 4th May, Brussels, ecancer´s Peter Goodwin talks to Ana Vivancos about her pioneering research in cancer genomics and work contributing to improved phase I clinical studies and best therapies for patients.
Related Posts
Gene expression improves the definition of a breast cancer subtype
ØThe study conducted by the Vall d’Hebron Institute of Oncology (VHIO) in conjunction with the GEICAM cooperative group and other American and Canadian researchers has led to a change in the definition of hormone-sensitive breast tumours
20 Dec 2012
Study shows marital status could impact on breast cancer prognosis
• An international study, with the participation of over 500,000 women, reveals that women who are married when diagnosed with breast cancer have a better chance of survival, regardless of tumor characteristics
• The study, in which the Vall d´Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO) have participated, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
28 May 2014
BIB launches portal to promote Catalan bioinformatics platform
Bioinformatics Barcelona (BIB), launched in 2014, constitutes a regionally-based multi-center bioinformatics platform as part of a joint initiative of the…
15 Jun 2016
VHIO joins 13 partner-strong consortium aimed at combating colorectal cancer
Announced today by lead partner Queen´s University Belfast, Northern Ireland, UK, a new European Consortium MErCuRIC comprised of 13 globally…
11 Dec 2013
Election results just in: Solange Peters to take the reins as ESMO President for the 2020-2021 term
The European Society for Medical Onocology (ESMO) has just announced that the President for 2020-2021 is Solange Peters, MD, PhD,…
28 Jun 2017
Josep Tabernero Co-authors NEJM Study Linking RAS Mutations to Vectibix Clinical Response in Patients With Metastatic Colorectal Cancer
Amgen today announced the publication of a biomarker analysis of Vectibix® (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based…
12 Sep 2013
Trio of VHIO talents awarded by AECC for research aimed at advancing cancer science and novel therapeutic approaches
Earlier this month the Spanish Association against Cancer (AECC) announced the results of its most recent Call. Among the awarded…
21 Jul 2017
Calling Young Scientists: deadline extended to 04 August to apply for EurocanPlatform´s Translational Cancer Research Course, 20 – 24 October 2014, Portugal
Aimed at exploring all aspects of the translational research continuum, from early detection through treatment to survivorship, this special 5-day…
10 Jul 2014
An independent nationwide evaluation ranks Vall d´Hebron´s Medical Oncology Service top of the leaderboard
According to the first independent, benchmark evaluation of the Spanish healthcare sector, Monitor de Reputación Sanitaria (MRS), issued by the…
04 Dec 2014
ASCO Annual Meeting 2012: Largest study on women with breast cancer treated with PI3K inhibitors
ASCO Annual Meeting 2012: Largest study on women with breast cancer treated with PI3K inhibitors.
– The study was presented at the annual meeting of ASCO (American Society of Clinical Oncology) revealing findings surrounding the largest sample of breast cancer patients treated with this group of drugs.
– This research presented at ASCO was honored through a Merit Award from the Conquer Cancer Foundation — testament to its high quality and important scientific interest.
06 Jun 2012
VHIO collaborates in study identifying a novel therapeutic target for triple-negative breast cancer
• The PIM1 proto-oncogene evidenced as new therapeutic target through which to sensitize triple-negative breast tumours to chemotherapy• PIM1…
05 Nov 2016
The ”la Caixa” Banking Foundation pays homage to medical researchers
Source: the ”la Caixa” Banking Foundation Josep Baselga, María Blasco, Valentí Fuster, Maite Mendioroz, Eduard Gratacós, Bonaventura Clotet and Pedro…
06 Sep 2017
EurOPDX: PDX and optimal preclinical study design in partnership
A vital tool in current armory against cancer is the development of patient-derived tumor xenograft (PDX) mouse models that faithfully…
07 Apr 2015
Registration open to attend VHIO´s Meet the Editor with Cancer Cell´s Li-Kuo Su 14 January
Li-Kuo Su, Editor-in-Chief of Cancer Cell will join us at the Hotel Alimara, Monday 14 January 2013, 09:00 – 10:15, …
22 Nov 2012
